ABVC BioPharma (ABVC) Stock Price, News & Analysis

Company Overview

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Key Stats

• Today's Range: $0.53 to $0.56
• 50-Day Range: $0.47 to $0.68
• 52-Week Range: $0.41 to $1.73
• Volume: 57,793 shs
• Average Volume: 131,483 shs
• Market Capitalization: $7.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ABVC BioPharma Stock Analysis - MarketRank™

ABVC BioPharma scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for ABVC BioPharma.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of ABVC BioPharma is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ABVC BioPharma is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ABVC BioPharma has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.24% of the float of ABVC BioPharma has been sold short.

Short Interest Ratio / Days to Cover

ABVC BioPharma has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ABVC BioPharma has recently decreased by 42.63%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ABVC BioPharma does not currently pay a dividend.

Dividend Growth

ABVC BioPharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.24% of the float of ABVC BioPharma has been sold short.

Short Interest Ratio / Days to Cover

ABVC BioPharma has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ABVC BioPharma has recently decreased by 42.63%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.0 / 5
• News Sentiment: -0.22

News Sentiment

ABVC BioPharma has a news sentiment score of -0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for ABVC BioPharma this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ABVC BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.90% of the stock of ABVC BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 11.38% of the stock of ABVC BioPharma is held by institutions.

ABVC Stock Analysis - Frequently Asked Questions

How have ABVC shares performed this year?

ABVC BioPharma's stock was trading at $0.59 at the beginning of 2025. Since then, ABVC stock has decreased by 8.3% and is now trading at $0.5412.
View the best growth stocks for 2025 here.

How were ABVC BioPharma's earnings last quarter?

ABVC BioPharma, Inc. (NASDAQ:ABVC) announced its quarterly earnings results on Monday, April, 3rd. The company reported ($1.50) earnings per share for the quarter, topping analysts' consensus estimates of ($1.90) by $0.40. The firm earned $0.59 million during the quarter, compared to analyst estimates of $0.03 million. ABVC BioPharma had a negative net margin of 1,619.65% and a negative trailing twelve-month return on equity of 104.94%.

When did ABVC BioPharma's stock split?

ABVC BioPharma's stock reverse split before market open on Tuesday, July 25th 2023. The 1-10 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did ABVC BioPharma IPO?

ABVC BioPharma (ABVC) raised $7 million in an initial public offering (IPO) on Tuesday, August 3rd 2021. The company issued 1,100,000 shares at $6.25 per share.

How do I buy shares of ABVC BioPharma?

Shares of ABVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ABVC BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ABVC BioPharma investors own include Meta Platforms (META), NIO (NIO), ObsEva (OBSV), Tesla (TSLA), Alibaba Group (BABA), ChargePoint (CHPT) and Walt Disney (DIS).

Company Calendar

• Last Earnings: 4/03/2023
• Today: 1/21/2025
• Next Earnings (Estimated): 3/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ABVC
• CUSIP: N/A
• CIK: 1173313
• Web: www.abvcpharma.com
• Phone: (510)-668-0881
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-10,520,000.00
• Net Margins: -1,619.65%
• Pretax Margin: -1,699.98%
• Return on Equity: -104.94%
• Return on Assets: -56.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.34
• Quick Ratio: 0.34

Sales & Book Value

• Annual Sales: $150,000.00
• Price / Sales: 46.83
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.02 per share
• Price / Book: 0.53

Miscellaneous

• Outstanding Shares: 12,980,000
• Free Float: 11,431,000
• Market Cap: $7.02 million
• Optionable: Not Optionable
• Beta: 0.70